هذه القائمة هي تحليل بناءً على أحداث السوق الأخيرة. إنها ليست توصية للاستثمار.
حول
PILA PHARMA AB (publ) operates as a clinical stage pharmaceutical company in Sweden. It is developing XEN-D0501, a TRPV1 antagonist that has completed two phase 2b clinical trials for type 2 diabetes. The company was incorporated in 2014 and is based in Malmö, Sweden.